Who is eligible for clinical trial NCT02947750?

Participants must meet the protocol's inclusion criteria for Renal Insufficiency, Chronic. The stated age range is 18 Years to 75 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT02947750 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-05-14

Neurovascular Transduction During Exercise in Chronic Kidney Disease (NCT02947750)

Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Emory University

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to find out why patients with chronic kidney disease (CKD) have poor exercise capacity and to explore what causes an increase in blood pressure during exercise (i.e. increased adrenaline levels, or decreased ability of blood vessels to dilate). This study will also test whether or not regular exercise on a bicycle and/or treatment with 6R-BH4 (Kuvan) pills, or histidine and beta-alanine supplementation improves these measures during exercise. 6R-BH4 is currently FDA-approved for use in patients with certain forms of a disease called phenylketonuria, but it is not currently FDA approved for blood pressure or exercise capacity in people with CKD.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (7 items) and avoid the listed exclusions (14 items).

Location: Emory University Hospital Midtown — Atlanta, Georgia

Age range: 18 Years to 75 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

for Chronic Kidney Disease Patients:
Stage III or IV Chronic Kidney Disease, defined as reduction in estimated glomerular filtration rate (eGFR) to 15-59 cc/minute as calculated by the modified Modification of Diet in Renal Disease (MDRD) Study equation or the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
Stable renal function, with no greater than a 30% reduction in eGFR over the prior 3 months
Does not exercise regularly (defined as exercising less than 20 minutes twice per week)
Willing and able to cooperate with the study protocol Inclusion Criteria for Control Study Participants:
Does not exercise regularly (defined as exercising less than 20 minutes twice per week)
Willing and able to cooperate with the study protocol

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
severe CKD (eGFR\<15 cc/minute)
ongoing drug or alcohol abuse
diabetic neuropathy
any serious systemic disease that might influence survival
severe anemia with hgb level \<9 g/dL
clinical evidence of congestive heart failure or ejection fraction below 35%
symptomatic heart disease determined by prior electrocardiogram, stress test, and/or history
treatment with central alpha agonists (clonidine)
uncontrolled hypertension with BP greater than 170/100 mm Hg
low blood pressure with BP less than 100/50
pregnancy or plans to become pregnant

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (3 Sites)

Emory University Hospital Midtown — Atlanta, Georgia
Emory University Hospital — Atlanta, Georgia
Atlanta VA Health Care System — Decatur, Georgia

📞 Contact the Study Coordinator

Phone: (404) 727-2525

Email: jeanie.park@emory.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Renal Insufficiency, Chronic

SDCC - Prospective Cohort Study of Chronic Renal Insufficiency — Oakland, California
A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD) — Ciudad de Buenos Aires,

Explore by condition: All Renal Insufficiency, Chronic clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗